Navigation Links
Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
Date:3/21/2013

months; secondary endpoints include changes in weight, FPG, PPG, tolerability, and other measures of safety and efficacy.

Michelle Baron , MD, FACE, Vice President and Chief Medical Officer of Intarcia, commented on the initiation of the FREEDOM Phase 3 program: "We named our program 'FREEDOM' in recognition of the burden that patients with type 2 diabetes face every day of their lives, and our sincere hope that ITCA 650 will alleviate some of that burden by achieving glucose control in a manner that optimizes patient adherence to therapy. It is well documented that sub-optimal adherence to medication results in poor outcomes and disproportionately higher medical costs. Our goal is to demonstrate that ITCA 650 can successfully deliver up to a full year of treatment from a single placement of the mini-pump – a potential breakthrough in addressing a huge unmet need in this chronic disease. We expect these studies to support regulatory submissions in both the U.S. and the EU, and anticipate the first clinical results in the second half of 2014."

"Our vision is to unleash a game-changing type 2 diabetes treatment that is so innovative and disruptive that it could truly reshape the standard of care and enable far better outcomes for the many patients suffering from this devastating disease," said Kurt Graves , Chairman, President and CEO of Intarcia. "Years of innovation and tenacity have paved the way for the first potential once-yearly type 2 diabetes medicine and the start of the FREEDOM program. We firmly believe that a once-yearly GLP-1 therapy that virtually ensures long-term compliance can do extremely well in any real-world outcomes comparative trials and in the payor-driven and outcomes-focused healthcare environment of the future. As a Company committed to delivering superior outcomes for patients, physicians, and payors, the enrollment of the first patient in our FREEDOM clinical s
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
3. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
4. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
5. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
6. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
7. PQA and CECity Launch Joint Venture to Deliver First National Pharmacy Quality Measurement, Benchmarking and Reporting Platform for Pharmacies and Health Plans
8. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
9. Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
10. Wyckoff Heights Medical Center Is First New York Hospital to Offer Asthmapolis Mobile Asthma Management Program
11. Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Inc. (NYSE: RMD ) today announced changes ... his position as Chief Executive Officer and President, and ... has appointed Dr. Peter C. Farrell, ResMed,s founder and ... and President, effective January 28, 2011.  Dr. Farrell will ...
... CardioGenics Holdings Inc. (OTC Bulletin Board: ... Merck Chimie SAS continue the commercialization process of ... while it is refining its encapsulation of the ... of magnetic beads coated with CardioGenics, proprietary silver-coating ...
Cached Medicine Technology:ResMed Inc. Announces Management Changes 2ResMed Inc. Announces Management Changes 3CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS 2CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS 3
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/9/2014)... the Keck School of Medicine of the University ... lacking a specific component of the immune system ... complication of infection. The discovery suggests that blocking ... in human autoimmune and hyper-inflammatory diseases such as ... study was published online on June 23 in ...
(Date:7/8/2014)... Memory Restoration has been awarded up to $15 million ... a four -year project aiming to help brain-injured people ... in neurosurgery, engineering, neurobiology, psychology and physics will collaborate ... in the brain. , Memory is the process in ... information, store it and retrieve it. Certain types of ...
(Date:7/8/2014)... A team of clinicians from Plymouth, UK, and Sydney, ... 10th July Australia) launched ACEmobile - a free-to-use app ... , ACEmobile is the first of its kind; an ... tool provides support through the whole process, meaning more ... out this type of assessment. Designed by clinicians for ...
(Date:7/8/2014)... 2014 In a study published yesterday in the ... La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify ... currently affects over 200 million people world wide. , ... be divided into small sections or ,neighborhoods., Scientists can ... primed for gene production, by looking for a marker on ...
Breaking Medicine News(10 mins):Health News:Discovery of a new means to erase pain 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2
... INDIANAPOLIS and MINNEAPOLIS, Aug. 19 WellPoint, Inc. (NYSE: ... RedBr i ck Hea l th ... entered into a strategic collaboration to create a new, behavior-based wellness ... health plan customers. , , Through an upcoming ...
... , WINSTON-SALEM, N.C., Aug. 19 A ... red blood cells, is now broadly available for the first time ... While scientists have long known of the benefits of fish and ... has proven that the omega-3 fatty acids found in fish dramatically ...
... , MURRIETA, Calif., Aug. 19 Forterus Inc. (Pink ... alcohol rehabilitation and other behavioral healthcare services, announced today revenues increased ... ended June 30, 2009 compared to revenues of $1.04 million, or ... , Forterus announced net income of $32,921, or $0.002 ...
... , LANHAM, Md., Aug. 19 ... immunization awareness campaign, Protecting our Future: The COSHAR Foundation ... new materials, including updated information about autism and vaccines and ... now. , , Through this ...
... modern drug, but not the most common, experts say, , ... remedy called "thunder god vine" helps reduce inflammation in people ... is an extract of the medicinal plant Tripterygium wilfordii ... gong teng" -- and has been used for centuries to ...
... , , NASHVILLE, ... managed care market intelligence, reports that while commercial pharmacy ... July 2008 and January 2009, commercial pharmacy benefit enrollment ... only a two percent decline over the same time ...
Cached Medicine News:Health News:WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs 2Health News:WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs 3Health News:WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs 4Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 2Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 3Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 4Health News:Forterus Inc. Posts Revenue, Net Income Gains 2Health News:COSHAR Foundation Enhances National Childhood Immunization Awareness Campaign 2Health News:Herb Shows Potential for Rheumatoid Arthritis 2Health News:Herb Shows Potential for Rheumatoid Arthritis 3Health News:Miami-Area Experienced Fewer Fluctuations in Pharmacy Benefit Enrollment Than Other Florida Markets 2
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously....
The ACE Alera clinical chemistry system serves a wide variety of chemistry diagnostic needs with the power of a large floor model analyzer in an easily integrated and economizing compact footprint of...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: